Do analysts rate PMCB or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PMCB or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$2.31 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is PMCB or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Nuvilex's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Genenta Science N/A N/A N/A

Do analysts prefer PMCB or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 500.96%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, PMCB or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$2.31 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is PMCB or KTTA more profitable?

Nuvilex's return on equity of -12.99% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Pasithea Therapeutics N/A -49.49% -46.81%

Do analysts recommend DYAI or PMCB?

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 621.15%. Given Dyadic International's stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ALVR or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ALVR or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Nuvilex N/A N/A -$19.42M -$2.31 N/A

Is ALVR or PMCB more profitable?

Nuvilex's return on equity of -12.99% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Nuvilex N/A -12.99% -8.92%

Do analysts rate APLT or PMCB?

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APLT or PMCB more profitable?

Nuvilex's return on equity of -12.99% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Nuvilex N/A -12.99% -8.92%

Nuvilex (PMCB) Competitors

$0.44 -0.02 (-3.37%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.44 +0.00 (+0.23%)

As of 09/25/2026 07:53 PM Eastern

Compare

PMCB vs. GNTA, KTTA, DYAI, ALVR, and APLT

Should you buy Nuvilex stock or one of its competitors? Nuvilex's main competitors and comparable companies include Genenta Science (GNTA), Pasithea Therapeutics (KTTA), Dyadic International (DYAI), AlloVir (ALVR), and Applied Therapeutics (APLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvilex compare to Genenta Science?

Nuvilex (NASDAQ:PMCB) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Nuvilex has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genenta Science's return on equity of 0.00% beat Nuvilex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Genenta Science	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Nuvilex's average media sentiment score of 1.82 beat Genenta Science's score of 1.79 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Genenta Science	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Genenta Science beats Nuvilex on 5 of the 7 factors compared between the two stocks.

How does Nuvilex compare to Pasithea Therapeutics?

Nuvilex (NASDAQ:PMCB) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 500.96%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvilex's return on equity of -12.99% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Nuvilex has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Nuvilex's average media sentiment score of 1.82 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nuvilex	Very Positive
Pasithea Therapeutics	Very Positive

Summary

Nuvilex beats Pasithea Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Nuvilex compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dyadic International has higher revenue and earnings than Nuvilex. Dyadic International is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	5.39	-$7.36M	-$0.23	N/A
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A

Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Nuvilex has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Nuvilex's return on equity of -12.99% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Nuvilex	N/A	-12.99%	-8.92%

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 621.15%. Given Dyadic International's stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Dyadic International had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.82 beat Dyadic International's score of 0.91 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyadic International	Positive
Nuvilex	Very Positive

Summary

Dyadic International beats Nuvilex on 9 of the 15 factors compared between the two stocks.

How does Nuvilex compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Nuvilex's return on equity of -12.99% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Nuvilex	N/A	-12.99%	-8.92%

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Nuvilex is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A

In the previous week, Nuvilex had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Nuvilex and 0 mentions for AlloVir. Nuvilex's average media sentiment score of 1.82 beat AlloVir's score of 0.00 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Nuvilex	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nuvilex beats AlloVir on 8 of the 11 factors compared between the two stocks.

How does Nuvilex compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Nuvilex's average media sentiment score of 1.82 beat Applied Therapeutics' score of 0.00 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Nuvilex	Very Positive

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Nuvilex has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex's return on equity of -12.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Nuvilex	N/A	-12.99%	-8.92%

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 11.0% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Applied Therapeutics and Nuvilex tied by winning 6 of the 12 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.74M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.19	14.15	275.82	25.78
Price / Sales	N/A	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	0.17	15.28	10.44	6.30
Net Income	-$19.42M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-4.07%	-2.94%	-1.31%	-0.23%
1 Month Performance	-18.36%	-8.80%	-4.61%	-4.16%
1 Year Performance	-54.63%	28.99%	15.01%	4.58%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	1.282 of 5 stars	$0.44 -3.4%	N/A	-54.6%	$4.74M	N/A	N/A	2	Positive News
GNTA Genenta Science	1.1684 of 5 stars	$0.76 +2.5%	N/A	-77.9%	$17.49M	N/A	N/A	9	Positive News Analyst Downgrade Gap Up
KTTA Pasithea Therapeutics	3.8327 of 5 stars	$0.51 +3.4%	$3.00 +492.1%	-31.4%	$16.37M	N/A	N/A	5
DYAI Dyadic International	2.5963 of 5 stars	$0.42 +5.2%	$3.00 +608.0%	-62.2%	$16.13M	$3.09M	N/A	5	News Coverage
ALVR AlloVir	N/A	$3.18 -0.6%	N/A	-38.8%	$16.04M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. GNTA, KTTA, DYAI, ALVR, and APLT

How does Nuvilex compare to Genenta Science?

Summary

How does Nuvilex compare to Pasithea Therapeutics?

Summary

How does Nuvilex compare to Dyadic International?

Summary

How does Nuvilex compare to AlloVir?

Summary

How does Nuvilex compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. GNTA, KTTA, DYAI, ALVR, and APLT

How does Nuvilex compare to Genenta Science?

Which has more risk & volatility, PMCB or GNTA?

Do insiders and institutionals have more ownership in PMCB or GNTA?

Is PMCB or GNTA more profitable?

Which has stronger earnings & valuation, PMCB or GNTA?

Does the media prefer PMCB or GNTA?

Do analysts rate PMCB or GNTA?

Summary

How does Nuvilex compare to Pasithea Therapeutics?

Do analysts prefer PMCB or KTTA?

Which has higher valuation & earnings, PMCB or KTTA?

Do institutionals & insiders have more ownership in PMCB or KTTA?

Is PMCB or KTTA more profitable?

Which has more risk and volatility, PMCB or KTTA?

Does the media prefer PMCB or KTTA?

Summary

How does Nuvilex compare to Dyadic International?

Do institutionals and insiders believe in DYAI or PMCB?

Which has better valuation and earnings, DYAI or PMCB?

Which has more risk and volatility, DYAI or PMCB?

Is DYAI or PMCB more profitable?

Do analysts recommend DYAI or PMCB?

Does the media favor DYAI or PMCB?

Summary

How does Nuvilex compare to AlloVir?

Is ALVR or PMCB more profitable?

Do insiders and institutionals believe in ALVR or PMCB?

Which has more volatility & risk, ALVR or PMCB?

Which has preferable valuation and earnings, ALVR or PMCB?

Does the media refer more to ALVR or PMCB?

Do analysts rate ALVR or PMCB?

Summary

How does Nuvilex compare to Applied Therapeutics?

Does the media prefer APLT or PMCB?

Which has more risk & volatility, APLT or PMCB?

Which has preferable earnings and valuation, APLT or PMCB?

Do analysts rate APLT or PMCB?

Is APLT or PMCB more profitable?

Do institutionals and insiders have more ownership in APLT or PMCB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools